Latest Biologicals News

Cambium Bio has raised just over A$1 million through a strategic placement at a 17% premium, boosting a key shareholder’s stake as it advances its pivotal Phase 3 trial for dry eye disease.

RLF AgTech is advancing its commercial growth strategy by expanding its nutrition and biologicals portfolio and rebuilding its Australian sales function, achieving a six-fold increase in customer receipts since early 2026.

TrivarX has locked in investigational product supply critical for starting its Phase 1 clinical trial of the Stabl-Im MRI imaging platform, targeting a 2026 trial commencement.

Chimeric Therapeutics reports encouraging interim data from its Phase 1/2 trial of CHM CDH17 CAR-T therapy, with tumour shrinkage up to 40% and stable disease maintained for months at the highest dose level.

Livestock Improvement Corporation reported a 6.7% revenue increase to NZD 314.8 million for FY26, but net profit after tax fell 30.4% to NZD 21.3 million due to significant technology investments. The co-operative declared a 12.26 cent dividend, maintaining strong underlying earnings and a debt-free balance sheet.

Mesoblast has completed treatment of 300 patients in its pivotal Phase 3 trial for rexlemestrocel-L, targeting chronic low back pain due to degenerative disc disease, with topline results expected mid-2027.

Immutep’s INSIGHT-003 trial shows promising overall survival in first-line non-squamous NSCLC, yet the Phase III TACTI-004 trial was discontinued following a futility analysis. Ongoing root cause investigations aim to clarify the divergent outcomes.

Cryosite Limited reported an 18% rise in FY2026 revenue to $16.7 million, with EBITDA growing 27% amid completed and ongoing facility expansions. The company aims to convert new capacity into client growth in FY2027.

RareX Limited’s latest metallurgical program at Cummins Range delivers a breakthrough 9.5x upgrade in rare earth concentrate grade and confirms a viable gallium by-product extraction pathway, setting the stage for integrated multi-element processing.

Mesoblast Limited’s Ryoncil® posted US$36 million in Q4 revenue, driving a full-year total of US$115 million, exceeding initial forecasts. The FDA-approved stem cell therapy for pediatric graft-versus-host disease shows robust uptake across US pediatric centres.

West Cobar Metals (ASX: WC1) has identified promising high-grade scandium drill targets at its Salazar project, alongside metallurgical testwork indicating potential for lower-cost scandium production via atmospheric leaching and bioleaching.

Imugene has secured $11.12 million through a placement to advance its allogeneic CAR-T therapy azer-cel after early clinical data showed complete responses in BTKi-resistant lymphoma patients.